Interleukin-12 and host defense against murine Pneumocystis pneumonia

Infection and Immunity

Volumn 76, Issue 5, 2008, Pages 2130-2137

  Ruan, Sanbao ^a   McKinley, Laura ^b   Zheng, Mingquan ^b   Rudner, Xiaowen ^a   D'Souza, Alain ^a   Kolls, Jay K ^b   Shellito, Judd E ^a,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; PROTEIN P35; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FUNGAL RNA; INTERLEUKIN 12;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE REPLICATION; GENE TRANSFER; HOST RESISTANCE; IMMUNOREACTIVITY; IN VIVO GENE TRANSFER; INFLAMMATORY CELL; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CELL COUNT; CHEMISTRY; CYTOLOGY; DRUG INSTILLATION; GENE THERAPY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE; LYMPHOCYTE DEPLETION; MICROBIOLOGY; MOUSE MUTANT; NEUTROPHIL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYTOKINES; FEMALE; GENE THERAPY; INSTILLATION, DRUG; INTERLEUKIN-12; LUNG; LYMPHOCYTE DEPLETION; LYMPHOCYTES; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUTROPHILS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, FUNGAL; T-LYMPHOCYTE SUBSETS;

EID: 42949159328     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00065-08     Document Type: Article

References (56)

1. Arulanandam, B. P., M. O'Toole, and D. W. Metzger. 1999. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis. 180:940-949.
2. Beck, J., M. Warnock, J. Curtis, M. Sniezek, S. Arrag-Peffer, H. Kaltreider, and J. Shellito. 1991. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am. J. Respir. Cell Mol. Biol. 5:186-197.
3. Beck, J., M. Warnock, H. Kaltreider, and J. Shellito. 1993. Host defenses against Pneumocystis carinii in mice selectively depleted of CD4+ lymphocytes. Chest 103:116S-118S.
4. Belyakov, I. M., J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B. Moss, W. Strober, and J. A. Berzofsky. 1998. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Investig. 102:2072-2081.
5. Bosma, G. C., R. P. Custer, and M. J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530.
6. Bramson, J., M. Hitt, W. S. Gallichan, K. L. Rosenthal, J. Gauldie, and F. L. Graham. 1996. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7:333-342.
7. Carreno, V., and J. A. Quiroga. 1997. Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection. I. Viral Hepat. 4(Suppl. 2):83-86.
8. Comley, J. C., and A. M. Sterling. 1994. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J. Eukaryot. Microbiol. 41:540-546.
9. Cooper, A. M., and S. A. Khader. 2007. IL-12p40: an inherently agonistic cytokine. Trends Immunol. 28:33-38.
10. Crothers, K., C. B. Beard, J. Turner, G. Groner, M. Fox, A. Morris, S. Eiser, and L. Huang. 2005. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 19:801-805.
11. Denis, M., and E. Ghadirian. 1994. Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. AIDS Res. Hum. Retrovir. 10:1619-1627.
12. Ducken, N. S., S. Olmos, D. M. Durrant, and D. W. Metzger. 2005. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect. Immun. 73:2306-2311.
13. Flynn, J. L., M. M. Goldstein, K. J. Triebold, J. Sypek, S. Wolf, and B. R. Bloom. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515-2524.
14. Gazzinelli, R. T., S. Hieny, T. A. Wynn, S. Wolf, and A. Sher. 1993. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. USA 90:6115-6119.
15. Gazzinelli, R. T., M. Wysocka, S. Hayashi, E. Y. Denkers, S. Hieny, P. Caspar, G. Trinchieri, and A. Sher. 1994. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153:2533-2543.
16. Geng, Y., K. Berencsi, Z. Gyulai, T. Valyi-Nagy, E. Gonczol, and G. Trinchieri. 2000. Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection. Infect. Immun. 68:2245-2253.
17. Goebel, A., E. Kavanagh, A. Lyons, I. B. Saporoschetz, C. Soberg, J. A. Lederer, J. A. Mannick, and M. L. Rodrick. 2000. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann. Surg. 231:253-261.
18. Greenberger, M., S. Kunkel, R. Strieter, N. Lukacs, J. Bramson, J. Gauldie, F. Graham, M. Hitt, J. Danforth, and T. Standiford. 1996. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J. Immunol. 157:3006-3012.
19. Harrison, T. S., and S. M. Levitz. 1996. Role of IL-12 in peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection. J. Immunol. 156:4492-4497.
20. Heinzel, F. P., F. Ahmed, A. M. Hujer, and R. M. Rerko. 1995. Immunoregulation of murine leishmaniasis by interleukin-12. Res. Immunol. 146: 575-581.
21. Hsieh, C. S., S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O'Garra, and K. M. Murphy. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549.
22. Huber, V. C., B. P. Arulanandam, P. M. Arnaboldi, M. K. Elmore, C. E. Sheehan, B. V. Kallakury, and D. W. Metzger. 2003. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol. 3:801-809.
23. Jacobson, M. A., J. Spritzler, A. Landay, E. Chan, D. Katzenstein, B. Schock, L. Fox, J. Roe, S. Kundu, and R. Pollard. 2002. A phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 16:1147-1154.
24. Kawakami, K., M. Tohyama, Q. Xie, and A. Saito. 1996. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin. Exp. Immunol. 104:208-214.
25. Kazanjian, P. H., D. Fisk, W. Armstrong, Q. Shulin, H. Liwei, Z. Ke, and S. Meshnick. 2004. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. J. Infect. Dis. 189:1684-1687.
26. Kobayashi, K., T. Kasama, J. Yamazaki, M. Hosaka, T. Katsura, T. Mochizuki, K. Soejima, and R. M. Nakamura. 1995. Protection of mice from Mycobacterium avium infection by recombinant interleukin-12. Antimicrob. Agents Chemother. 39:1369-1371.
27. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827-845.
28. Kobayashi, M., H. Takahashi, D. N. Herndon, R. B. Pollard, and F. Suzuki. 2003. Therapeutic effects of IL-12 combined with benzoylmesaconine, a non-toxic aconitine-hydrolysate, against herpes simplex virus type 1 infection in mice following thermal injury. Burns 29:37-42.
29. Kolls, J., D. Lei, G. Odom, S. Nelson, W. Summer, M. Gerber, and J. Shellito. 1996. Transient CD4-lymphocyte depletion prolongs transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7:489-497.
30. Kolls, J., C. Vazquez, D. Lei, P. Schwarzenberger, P. Ye, S. Nelson, W. Summer, and J. Shellito. 1999. Interferon-gamma and CD8+ T-cells restore host defense against P. carinii in mice lacking CD4+ T-cells. J. Immunol. 162:2890-2894.
31. Lieberman, L. A., and C. A. Hunter. 2002. Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells. Microbes Infect. 4:1531-1538.
32. Lundberg, B. E., A. J. Davidson, and W. J. Burman. 2000. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS 14:2559-2566.
33. MacDonald, H. R., R. C. Budd, and J. C. Cerottini. 1990. Pgp-1 (Ly 24) as a marker of murine memory T lymphocytes. Curr. Top. Microbiol. Immunol. 159:97-109.
34. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199-1204.
35. Masur, H., M. Michelis, J. Greene, I. Onorato, R. Vande Stouwe, R. Holzman, G. Wormser, L. Brettman, M. Lange, H. Murray, and S. Cunningham-Rundles. 1981. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med. 305:1431-1438.
36. McAllister, F., S. Ruan, C. Steele, M. Zheng, L. McKinley, L. Ulrich, L. Marrero, J. E. Shellito, and J. K. Kolls. 2006. CXCR3 and IFN protein-10 in Pneumocystis pneumonia. J. Immunol. 177:1846-1854.
37. Melero, I., G. Mazzolini, I. Narvaiza, C. Qian, L. Chen, and J. Prieto. 2001. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol. 22:113-115.
38. Meshnick, S. R., P. A. Hossler, K. S. Enger, P. Kazanjian, J. S. Rest, D. Mindell, B. Li, C. H. Lee, L. F. Nimri, J. L. Carter, C. B. Beard, and L. Huang. 2001. Distribution of DHPS mutations among ITS subtypes of P. carinii f. sp. hominis. J. Eukaryot. Microbiol. 48(Suppl.):126S-128S.
39. Monteiro, J. M., C. Harvey, and G. Trinchieri. 1998. Role of interleukin-12 in primary influenza virus infection. J. Virol. 72:4825-4831.
40. Morris, A., J. D. Lundgren, H. Masur, P. D. Walzer, D. L. Hanson, T. Frederick, L. Huang, C. B. Beard, and J. E. Kaplan. 2004. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10:1713-1720.
41. Okamura, H., S. Kashiwamura, H. Tsutsui, T. Yoshimoto, and K. Nakanishi. 1998. Regulation of interferon-gamma production by IL-12 and IL-18. Curr. Opin. Immunol. 10:259-264.
42. Oppmann, B., R. Lesley, B. Bloom, J. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, F. Zonin, E. Vaisberg, T. Churakova, M. Liu, D. Gorman, J. Wagner, S. Zurawski, Y. Liu, J. Abrams, K. Moore, D. Rennick, R. Waal-Malefyt, C. Hannum, J. Bazan, and R. Kastelein. 2000. Novel p19 protein engages IL-12 p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725.
43. Oxenius, A., U. Karrer, R. M. Zinkernagel, and H. Hengartner. 1999. IL-12 is not required for induction of type 1 cytokine responses in viral infections. J. Immunol. 162:965-973.
44. Pammit, M. A., V. N. Budhavarapu, E. K. Raulie, K. E. Klose, J. M. Teale, and B. P. Arulanandam. 2004. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob. Agents Chemother. 48:4513-4519.
45. Pockros, P. J., K. Patel, C. O'Brien, M. Tong, C. Smith, V. Rustgi, R. L. Carithers, J. G. McHutchison, E. Olek, and M. F. Debruin. 2003. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 37:1368-1374.
46. Potvin, D. M., D. W. Metzger, W. T. Lee, D. N. Collins, and A. I. Ramsingh. 2003. Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4. J. Virol. 77:8272-8279.
47. Rothfuchs, A. G., A. Bafica, C. G. Feng, J. G. Egen, D. L. Williams, G. D. Brown, and A. Sher. 2007. Dectin-1 interaction with Mycobacterium tuberculosis leads to enhanced IL-12p40 production by splenic dendritic cells. J. Immunol. 179:3463-3471.
48. Rudner, X. L., K. I. Happel, E. A. Young, and J. E. Shellito. 2007. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 75:3055-3061.
49. Shellito, J., V. Suzara, W. Blumenfeld, J. Beck, H. Steger, and T. Ermak. 1990. A new model of Pneumocystis carinii infection in mice selctively depleted of helper T lymphocytes. J. Clin. Investig. 85:1686-1693.
50. Stampfli, M. R., G. Scott Neigh, R. E. Wiley, M. Cwiartka, S. A. Ritz, M. M. Hitt, Z. Xing, and M. Jordana. 1999. Regulation of allergic mucosal sensitization by interleukin-12 gene transfer to the airway. Am. J. Respir. Cell Mol. Biol. 21:317-326.
51. Strieter, R. M., J. A. Belperio, and M. P. Keane. 2003. Host innate defenses in the lung: the role of cytokines. Curr. Opin. Infect. Dis. 16:193-198.
52. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83-243.
53. Trinchieri, G. 1998. Proinflammatory and immunoregulatory functions of interleukin-12. Int. Rev. Immunol. 16:365-396.
54. Trinchieri, G., and P. Scott. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol. 146:423-431.
55. Wagner, R. D., H. Steinberg, J. F. Brown, and C. J. Czuprynski. 1994. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb. Pathog. 17:175-186.
56. Zar, J. 1974. Biostatistical analysis. Prentice-Hall, Inc., Englewood Cliffs, NJ.